1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Pfizer Ibrance Hopes Dashed In Early-Stage Breast Cancer

 
• By Joseph Haas

Data from the PENELOPE-B study in high-risk early breast cancer patients show no separation from placebo, compounding the earlier failure of the PALLAS trial in low- and high-risk patients.

New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.
With a second failed study, Pfizer's hopes for Ibrance in early breast cancer crash

Expectations were low for Pfizer Inc.’s Ibrance to find a way forward in neoadjuvant, early-stage breast cancer after the failure of the Phase II/III PALLAS study, but the door has fully closed on adding this setting to the CDK4/6 inhibitor’s label now that it also failed in the Phase III PENELOPE-B study in high-risk patients.

Pfizer and the German Breast Group, which sponsored the study, revealed on 9 October that Ibrance (palbociclib) added to standard adjuvant endocrine therapy did not show an invasive disease-free survival...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D